All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?
Featured:
Jean-Jacques KiladjianDuring the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of polycythemia vera (PV)?
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?
Kiladjian discusses factors that are independently associated with a positive outcome with ropeginterferon alfa-2b therapy. In a cohort of patients from Hôpital Saint-Louis, two factors associated with such a potential operational cure were found: patients who received at least 2 years of ropeginterferon alfa-2b therapy with complete response, and the mutant allele burden of the JAK2 mutation.